The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG): Introduction, continuing work, and results of the radiotherapy reference panel

Strahlentherapie und Onkologie

Volumn 181, Issue 9, 2005, Pages 557-566

  Müller, Rolf Peter ^a   Eich, Hans Theodor ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Competence Network Malignant Lymphoma; Hodgkin's lymphoma; Quality assurance; Radiotherapy; Teleradiotherapy

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; EVALUATION; GERMANY; HEALTH CARE QUALITY; HODGKIN DISEASE; HUMAN; IMAGING SYSTEM; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; PRESCRIPTION; PROSPECTIVE STUDY; RADIATION DOSE; RETROSPECTIVE STUDY;

DISEASE-FREE SURVIVAL; GERMANY; HODGKIN DISEASE; HUMANS; MULTICENTER STUDIES; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY ASSURANCE, HEALTH CARE; RADIATION ONCOLOGY; RADIOISOTOPE TELETHERAPY; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS; REMOTE CONSULTATION; RETROSPECTIVE STUDIES; TELERADIOLOGY; TIME FACTORS;

EID: 25144478887     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-005-1437-0     Document Type: Article

References (28)

1. Bogner L, Scherer J, Treutwein M, et al. Verification of IMRT: techniques and problems. Strahlenther Onkol 2004;180:340-50.
2. Bolla M, Bartelink H, Garavaglia G, et al. EORTC guidelines for writing protocols for clinical trials of radiotherapy. Radiother Oncol 1995;36:1-8.
3. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee of Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1.
4. Dühmke E, Diehl V, Löffler M, et al. Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 1996;36:305-10.
5. Dühmke E, Franklin J, Pfreundschuh M, et al. Low-dose radiation is sufficient for the noninvolved extended field treatment in favourable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001;19:2905-14.
6. Eich HT, Haverkamp U, Engert A, et al. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma - a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 2005:in press.
7. Eich HT, Hero B, Staar S, et al. Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in Kadish stage C esthesioneuroblastoma. Strahlenther Onkol 2003;179:233-40.
8. Eich HT, Müller R-P, Ansen S, et al. Neue Therapiestrategien des Morbus Hodgkin in Kooperation von Radioonkologie und Internistischer Onkologie. Röntgenpraxis 2004;51:114-24.
9. Eich HT, Müller R-P, Schneeweiss A, et al. Initiation of a teleradiotherapeutic network for patients in German lymphoma studies. Int J Radiat Oncol Biol Phys 2004;58:805-8.
10. Eich HT, Staar S, Gossmann A, et al. Centralized radiation oncological review of cross sectional imaging of Hodgkin's disease leads to significant changes of the required involved field - results of a quality assurance program of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 2004;58:1120-6.
11. Eich HT, Staar S, Gossmann A, et al. The HD 12 panel of the German Hodgkin Lymphoma Study Group (GHSG) - a quality assurance program based on a multidisciplinary panel reviewing all patients' imaging. Am J Clin Oncol 2004;27:279-84.
12. Esik O, Csere T, Stefanits K, et al. Increased metabolic activity in the spinal cord of patients with long-standing Lhermitte's sign. Strahlenther Onkol 2003;179:690-3.
13. Fletcher BD, Glicksman AS, Gieser P. Interobserver variability in the detection of cervical-thoracic Hodgkin's disease by computed tomography. J Clin Oncol 1999;17:2153-9.
14. Herrmann T, Thiede G, Trott KR, et al. Offsprings of preconceptionally irradiated parents. Final report of a longitudinal study 1976-1994 and recommendations for patients' advisory. Strahlenther Onkol 2004;180:21-30.
15. Horiot JC, Johannson KA, Gonzales DG, et al. Quality assurance in the EORTC cooperative group of radiotherapy. 1. Assessment of radiotherapy staff and equipment. Radiother Oncol 1986;6:275-84.
16. Johannson KA, Horiot JC, van Dam J, et al. Quality assurance in the EORTC cooperative group of radiotherapy. 2. Dosimetric intercomparison. Radiother Oncol 1986;7:269-79.
17. Johannson KA, Horiot JC, van der Scheuren E. Quality assurance in the EORTC cooperative group of radiotherapy. 3. Intercomparison in an anatomical phantom. Radiother Oncol 1987;9:289-98.
18. Lehmann D, Leetz HK, Hodapp N, et al. Physical and technical quality assurance in the CHARTWEL-Bronchus trial. Strahlenther Onkol 2003;179:152-7.
19. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease. Cotswolds Meeting. J Clin Oncol 1989;7:1630-6.
20. Martin LA, Krall JM, Curran WJ, et al. Influence of a sampling review process for radiation quality assurance in cooperative group clinical trials - results of the Radiation Therapy Oncology Group (RTOG) analysis. Radiother Oncol 1995;36:9-14.
21. Mendenhall NP. Diagnostic procedures and guidelines for the evaluation and follow-up of Hodgkin's disease. Semin Radiat Oncol 1996;6:131-45.
22. Ott M, Schmidberger H, Wormann B, et al. Involved-field irradiation in combination with total-body irradiation (TBI) does not increase short-term toxicity compared to TBI alone in patients with advanced-stage low-grade non-Hodgkin lymphoma. Strahlenther Onkol 2002;178:245-51.
23. Pajonk F, Weissenberger C, Witucki G, et al. Vitiligo at the sites of irradiation in a patient with Hodgkin's disease. Strahlenther Onkol 2002;178:159-62.
24. Reinstein E, Peachey S, Laurie F, et al. Impact of a dosimetry review program on radiotherapy in group trials. Int J Radiat Oncol Biol Phys 1985;11:1179-84.
25. Sehlen S, Willich N, Müller R-P, et al. Final quality assurance of radiation therapy in early stages without risk factors of Hodgkin's disease in the German Hodgkin Study Group (HD4 and HD7). Cancer Res Clin Oncol 2004;130:Suppl 1:63.
26. Sehlen S, Willich N, Müller R P, et al. Final quality assurance of radiotherapy in early stages with risk factors of Hodgkin's disease in the HD8 study of the German Hodgkin Study Group - comparison of extended field and involved field radiotherapy. Cancer Res Clin Oncol 2004;130:Suppl 1:67.
27. Sminia P, Oldenburger F, Slotman BJ, et al. Re-irradiation of the human spinal cord. Strahlenther Onkol 2002;178:453-6.
28. Van der Scheuren E, Horiot JC, Leunens G, et al. Quality assurance in cancer treatment. Eur J Cancer 1993;29:181-4.